The estimated Net Worth of Norbert W Bischofberger is at least $23.2 Million dollars as of 27 June 2024. Dr Bischofberger owns over 615,518 units of Kronos Bio stock worth over $10,368,972 and over the last 21 years he sold KRON stock worth over $12,192,472. In addition, he makes $596,365 as Pres und CEO & Director at Kronos Bio.
Sign up
Dr D KRON stock SEC Form 4 insiders trading
Dr has made over 49 trades of the Kronos Bio stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 615,518 units of KRON stock worth $732,466 on 27 June 2024.
The largest trade he's ever made was buying 3,005,122 units of Kronos Bio stock on 10 June 2024 worth over $3,125,327. On average, Dr trades about 84,160 units every 65 days since 2003. As of 27 June 2024 he still owns at least 10,802,138 units of Kronos Bio stock.
You can see the complete history of Dr Bischofberger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Norbert W. Bischofberger Ph.D. biography
Dr. Norbert W. Bischofberger Ph.D. is the Pres, CEO & Director at Kronos Bio.
What is the salary of Dr D?
As the Pres und CEO & Director of Kronos Bio, the total compensation of Dr D at Kronos Bio is $596,365. There are 1 executives at Kronos Bio getting paid more, with Jorge F. DiMartino M.D., Ph.D. having the highest compensation of $765,105.
How old is Dr D?
Dr D is 65, he's been the Pres und CEO & Director of Kronos Bio since . There are no older and 10 younger executives at Kronos Bio.
What's Dr D's mailing address?
Norbert's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Insiders trading at Kronos Bio
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger und Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
What does Kronos Bio do?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
What does Kronos Bio's logo look like?
Complete history of Dr Bischofberger stock trades at Gilead Sciences, Morphic Inc, Vir Biotechnology Inc und Kronos Bio
Kronos Bio executives and stock owners
Kronos Bio executives and other stock owners filed with the SEC include:
-
Jorge F. DiMartino M.D., Ph.D.,
Chief Medical Officer & Exec. VP of Clinical Devel. -
Dr. Norbert W. Bischofberger Ph.D.,
Pres, CEO & Director -
Dr. Yasir B. Al-Wakeel BCh, BM, MA,
CFO & Head of Corp. Devel. -
Dr. Norbert W. Bischofberger,
Pres, CEO & Director -
David M. Tanen J.D.,
Sec. & Director -
Joshua A. Kazam,
Co-Founder & Director -
Marni Kottle,
Sr. VP of Corp. Communications & Investor Relations -
Dr. Christopher Dinsmore Ph.D.,
Chief Scientific Officer -
Barbara A. Kosacz J.D.,
COO & Gen. Counsel -
Charles Lin Ph.D.,
Sr. VP of Biology -
Dr. Pasit Phiasivongsa Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Stephanie Yao,
Exec. Director of Investor Relations & Corp. Communications -
Dr. Christopher Dinsmore,
Chief Scientific Officer -
Barbara A. Kosacz,
COO & Gen. Counsel -
Dr. Yasir B. Al-Wakeel,
CFO & Head of Corp. Devel. -
Norbert W Bischofberger,
PRESIDENT & CEO -
Barbara Kosacz,
COO & General Counsel -
Yasir B. Al Wakeel,
Chief Financial Officer -
Christopher Dinsmore,
Chief Scientific Officer -
Norbert W. & Inger A. Revoc...,
10% owner -
Arie Belldegrun,
-
Rebecka Belldegrun,
Director -
Jakob Loven,
Director -
John C Martin,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Jorge Di Martino,
Chief Medical Officer & VP -
Backer Marianne De,
Director -
Roshawn A. Blunt,
-
Roger D Dansey,
-
David M Tanen,
-
Joshua A Kazam,
-
Allison Frisbee,
SR VP, CORP OPERATIONS & LEGAL -
Charles Y Lin,
SR VP, RESEARCH & DEVELOPMENT -
Elizabeth A Olek,
SR VP, CLINICAL SCIENCE -
Taiyin Yang,
-
Elena Ridloff,
-
Katherine V Stultz,
-
Deborah Knobelman,
Chief Financial Officer